Neuronetics Appoints Robert Greene as Senior Vice President Sales
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) appointed Robert (Rob) Greene as Senior Vice President Sales, effective June 1, 2026. Greene has extensive commercial and sales leadership experience in healthcare and medical technology.
According to Neuronetics, he received an inducement grant of 200,000 RSUs vesting in four equal annual installments under Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
STIM gained 8.44% while peers were mixed: BSGM up 39.91%, CVRX up 0.74%, ELMD down 1.59%, TLSI down 7.1%, BWAY down 2.25%, suggesting a stock-specific reaction to company news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Strategic partnership | Positive | -13.9% | Collaboration with ANT Neuro to integrate neuronavigation into NeuroStar TMS. |
| May 05 | Earnings results | Positive | +7.4% | Q1 2026 revenue growth with guidance reiterated for full-year 2026. |
| Apr 29 | Inducement RSU grants | Neutral | +14.1% | Inducement RSUs totaling 122,400 shares for six new non-executive employees. |
| Apr 21 | Earnings call notice | Neutral | -5.1% | Announcement of date and time for Q1 2026 earnings release and call. |
| Apr 13 | Coverage expansion | Positive | +3.0% | Optum/UHC updated TMS policy expanding NeuroStar access and provider capacity. |
Recent news has more often seen price moves align with the perceived positivity or neutrality of announcements, though there are notable divergences on both positive partnership and neutral scheduling news.
Over the past few months, Neuronetics has reported several operational and strategic updates. A Q1 2026 earnings release highlighted revenue growth and reiterated full‑year guidance. A strategic collaboration with ANT Neuro aimed to enhance NeuroStar TMS with neuronavigation from the second half of 2026. Coverage expansion by Optum/United Healthcare broadened NeuroStar access across 26 states and Washington, D.C. plus 34.8 million covered lives. Multiple inducement and equity awards, including RSU grants, underscored ongoing investment in talent and governance, consistent with today’s senior sales appointment and related inducement grant.
Regulatory & Risk Context
An effective S-3 shelf dated March 17, 2026 registers up to 20,737,061 shares of common stock for resale by selling stockholders. The company will receive no proceeds from these sales, and the filing notes that the registered shares represent a significant percentage of outstanding common stock, which could affect market price if sold concurrently.
Market Pulse Summary
This announcement highlights Neuronetics’ focus on commercial execution by appointing a new Senior Vice President of Sales and granting 200,000 RSUs vesting over four years as an inducement. It follows recent operational updates, including collaborations and coverage expansions for NeuroStar. Investors may watch how sales traction evolves under new leadership, as well as potential effects from an effective S-3 registering 20,737,061 shares of common stock for resale by existing holders.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement grant financial
AI-generated analysis. Not financial advice.
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Robert Greene has been appointed as the company’s Senior Vice President Sales, effective June 1, 2026.
Rob brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service.
Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
In connection with his hiring on June 1, 2026, the Compensation Committee of the Company’s Board of Directors authorized the grant to Mr. Greene of restricted stock units representing 200,000 shares of the Company’s common stock in accordance with Nasdaq Listing Rule 5635(c)(4), which will vest in four equal annual installments on the anniversary of the grant date, subject to Mr. Greene’s continued employment with the company and subject to Capitalization Adjustments (as defined in the Company’s 2020 Inducement Incentive Plan).
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
